STOCK TITAN
  1. Home
  2. News
  3. RHHBY

Roche Holding AG - RHHBY STOCK NEWS

Welcome to our dedicated news page for Roche Holding (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roche Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roche Holding's position in the market.

News
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024
Rhea-AI Summary
Roche introduces navify Analytics and Monitoring solutions for laboratories and point of care services, aiming to enhance operational efficiency and financial outcomes. The suite offers actionable insights to improve productivity, reduce costs, and optimize test turnaround times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
-
News
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
Rhea-AI Summary
Roche and Alnylam's Phase II KARDIA-2 study of zilebesiran for hypertension met its primary endpoint, showing significant blood pressure reductions. The study demonstrated promising safety and tolerability, supporting potential twice-yearly dosing. The companies have initiated the Phase II KARDIA-3 study. Hypertension is a global health crisis with high mortality rates, affecting one in three adults worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
clinical trial
-
News
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Rhea-AI Summary
Roche's Xolair shows promising results in treating food allergies in NIH-sponsored Phase III study, leading to FDA approval for expanded use in children and adults. The study reveals increased tolerance to peanuts, tree nuts, egg, milk, and wheat in multi-food allergic patients as young as 1 year old, reducing the risk of severe allergic reactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
Rhea-AI Summary
Genentech, a member of the Roche Group, has received FDA approval for Xolair to reduce allergic reactions in patients with IgE-mediated food allergy. The approval is based on positive data from the NIH-sponsored Phase III OUtMATCH study, showing improved tolerance to food allergens in patients as young as 1 year old.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
fda approval
-
News
Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics
Rhea-AI Summary
Roche (RHHBY) partners with PathAI to develop AI digital pathology algorithms for companion diagnostics, aiming to advance precision medicine. The collaboration will enhance patient access to targeted treatments by integrating AI-interpretation into pathology labs globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
-
News
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)
Rhea-AI Summary
Genentech, a member of the Roche Group, announced new 72-week data from two global Phase III studies evaluating Vabysmo in macular edema due to branch and central retinal vein occlusion. The data showed that nearly 60% of people receiving Vabysmo were able to extend their treatment intervals to three or four months apart. Patients maintained vision gains and retinal drying for more than one year. Vabysmo is approved in the U.S. and more than 90 countries for people with wet AMD and DME.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
News
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
Rhea-AI Summary
Roche announces positive 72-week data from global Phase III studies evaluating Vabysmo in macular edema due to retinal vein occlusion. Up to 60% of patients were able to extend treatment intervals to three or four months apart. The drug maintained vision gains and retinal drying for more than a year, with well-tolerated safety profiles. Vabysmo is the first and only bispecific antibody approved for the eye, targeting angiopoietin-2 and vascular endothelial growth factor-A. It is approved in the US for RVO and in over 90 countries for nAMD and DME.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
News
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Rhea-AI Summary
Roche Group achieved a 1% growth in group sales at constant exchange rates, with a 7% decline in Swiss Franc. The Pharmaceuticals Division sales increased by 6%, and the Diagnostics Division sales were 13% lower. The company's net income increased by 7% to CHF 12.4 billion, and core earnings per share increased by 6% to CHF 18.57. The company expects an increase in Group sales in the mid-single-digit range for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
covid-19
-
News
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)
Rhea-AI Summary
Genentech, a member of the Roche Group, announced positive 72-week data from two global Phase III studies evaluating Vabysmo in macular edema due to branch and central retinal vein occlusion. The results showed nearly 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart. Patients maintained vision gains and retinal drying for more than one year, with Vabysmo being well tolerated. Vabysmo is the first and only bispecific antibody approved for the eye and is approved in more than 90 countries. The sustained vision improvements and retinal drying seen up to 72 weeks reaffirm Vabysmo as an effective treatment for retinal vein occlusion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
News
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Rhea-AI Summary
Roche announced that the European Commission has granted marketing authorization for Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy for subcutaneous injection. The new injection reduces treatment time by approximately 80% compared to standard IV infusion, with most injections taking between four and eight minutes. The approval is based on pivotal data from the Phase IB/III IMscin001 study, showing comparable levels of Tecentriq in the blood when administered subcutaneously, and a safety and efficacy profile consistent with the IV formulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
Stock RHHBY logo
Roche Holding AG

OTC:RHHBY

RHHBY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

RHHBY Stock Data

199.10B
727.48M
0.15%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Basel